apyx medical corporation, a energy technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. it operates in two segments, advanced energy and original equipment manufacturing (oem). the company develops j-plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue. it markets and sells helium plasma technology under the renuvion brand name in the cosmetic surgery market and under the j-plasma brand name in the hospital surgical market. the company's renuvion cosmetic technology enables plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue; and the j-plasma system allows surgeons to operate in eliminating unintended tissue trauma. it also designs, develops, manufactures, and sells electrosurgical and oem generators and related accessories for medical device manufacturers. the company was formerly known as bovie medical corporation and changed
Company profile
Ticker
APYX
Exchange
Website
CEO
Charles Goodwin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AN CON GENETICS INC, BOVIE MEDICAL CORP, BOVIE MEDICAL Corp
SEC CIK
Corporate docs
Subsidiaries
Apyx China Holding Corp. • Apyx SY Medical Devices (NINGBO) Co., LTD. ...
IRS number
112644611
APYX stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
21 Mar 24
8-K
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2023 Financial Results; Introduces Full Year 2024 Financial Outlook
21 Mar 24
8-K
Other Events
21 Feb 24
8-K
Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication
22 Jan 24
8-K
Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2023 Revenue Results
8 Jan 24
8-K
Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer
28 Nov 23
S-8
Registration of securities for employees
16 Nov 23
8-K
Departure of Directors or Certain Officers
16 Nov 23
S-8
Registration of securities for employees
16 Nov 23
8-K
Apyx Medical Corporation Announces New Debt Facility with Perceptive Advisors
9 Nov 23
Transcripts
APYX
Earnings call transcript
2023 Q4
21 Mar 24
APYX
Earnings call transcript
2023 Q3
9 Nov 23
APYX
Earnings call transcript
2023 Q2
10 Aug 23
APYX
Earnings call transcript
2023 Q2
1 Aug 23
APYX
Earnings call transcript
2023 Q1
11 May 23
APYX
Earnings call transcript
2022 Q4
16 Mar 23
APYX
Earnings call transcript
2022 Q3
10 Nov 22
APYX
Earnings call transcript
2022 Q2
14 Aug 22
APYX
Earnings call transcript
2022 Q1
12 May 22
APYX
Earnings call transcript
2021 Q4
17 Mar 22
Latest ownership filings
SC 13G/A
HIRSCHMAN ORIN
25 Mar 24
SC 13G/A
PURA VIDA INVESTMENTS, LLC
14 Feb 24
SC 13G/A
Divisadero Street Capital Management, LP
14 Feb 24
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
Archon Capital Management LLC
13 Feb 24
SC 13G/A
HIRSCHMAN ORIN
7 Feb 24
SC 13G/A
Cowen Financial Products LLC
2 Feb 24
SC 13G
ROYCE & ASSOCIATES LP
23 Jan 24
SC 13G/A
ROYCE & ASSOCIATES LP
23 Jan 24
4
MOSHE CITRONOWICZ
11 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 22.13 mm | 22.13 mm | 22.13 mm | 22.13 mm | 22.13 mm | 22.13 mm |
Cash burn (monthly) | (no burn) | (no burn) | 1.66 mm | 1.50 mm | (no burn) | 632.25 k |
Cash used (since last report) | n/a | n/a | 9.97 mm | 8.98 mm | n/a | 3.79 mm |
Cash remaining | n/a | n/a | 12.17 mm | 13.15 mm | n/a | 18.35 mm |
Runway (months of cash) | n/a | n/a | 7.3 | 8.8 | n/a | 29.0 |
Institutional ownership, Q2 2023
64.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 58 |
Opened positions | 12 |
Closed positions | 8 |
Increased positions | 14 |
Reduced positions | 21 |
13F shares | Current |
---|---|
Total value | 91.55 bn |
Total shares | 22.23 mm |
Total puts | 1.90 k |
Total calls | 122.70 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Archon Capital Management | 3.45 mm | $17.36 bn |
Divisadero Street Capital Management | 2.28 mm | $11.49 bn |
RTW Investments | 1.78 mm | $8.94 bn |
Cowen Financial Products | 1.78 mm | $4.16 mm |
Hirschman Orin | 1.69 mm | $11.81 mm |
Royce & Associates | 1.60 mm | $8.06 bn |
Vanguard | 1.48 mm | $7.44 bn |
AIGH Capital Management | 1.27 mm | $6.37 bn |
Pura Vida Investments | 988.59 k | $4.97 bn |
Horizon Kinetics Asset Management | 615.00 k | $3.09 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Jan 24 | Goodwin Charles D. II | Stock Option (Option to Buy) Common Stock | Grant | Acquire A | No | No | 2.42 | 243,000 | 588.06 k | 0 |
10 Jan 24 | Moshe Citronowicz | Stock Option (Option to Buy) Common Stock | Grant | Acquire A | No | No | 2.42 | 72,000 | 174.24 k | 0 |
10 Jan 24 | Todd Hornsby | Stock Option (Option to Buy) Common Stock | Grant | Acquire A | No | No | 2.42 | 100,000 | 242.00 k | 0 |
10 Jan 24 | Matthew C Hill | Stock Option (Option to Buy) Common Stock | Grant | Acquire A | No | No | 2.42 | 150,000 | 363.00 k | 0 |
12 Dec 23 | Matthew C Hill | Common Stock | Buy | Acquire P | No | No | 2.19 | 2,500 | 5.48 k | 2,500 |
News
Crude Oil Moves Lower; Accenture Shares Tumble After Q2 Results
21 Mar 24
Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
21 Mar 24
12 Health Care Stocks Moving In Thursday's Intraday Session
21 Mar 24
Gold Gains 1%; Micron Posts Upbeat Results
21 Mar 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
21 Mar 24
Press releases
Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2023 Financial Results on March 21, 2024
4 Mar 24
Apyx Medical Corporation Announces Renuvion to be Featured in Educational Sessions at the American Academy of Cosmetic Surgery (AACS) Scientific Meeting
21 Feb 24
Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Evaluating the Safety of Renuvion® Following Liposuction in Multiple Areas of the Body
22 Jan 24
Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2023 Revenue Results
8 Jan 24